Hemophilia Treatment Drugs Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2025
Zion Market Research has published a new report titled “Hemophilia Treatment Drugs Market by Product Type (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents), by Disease Type (Hemophilia A, Hemophilia B, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce) – Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024”. According to the report, global hemophilia treatment drugs market was valued at approximately USD 17.37 billion in 2017 and is expected to generate revenue of around USD 25.61 billion by the end of 2024, growing at a CAGR of around 5.7% between 2017 and 2024.
Hemophilia is a genetic disorder in which the blood clotting factors are reduced; this hampers the function of blood clotting and leads to abnormal internal and external bleeding after any type of injuries. Hemophilia A and hemophilia B are the main types of hemophilia which are commonly seen in patients. Hemophilia A occurs when clotting factor VIII is reduced whereas hemophilia B occurs when clotting factor IX is reduced. Hemophilia C and parahemophilia are rare types of hemophilia which occur when there is a reduction in clotting factor XI and clotting factor V respectively.
Download Free Sample Report of Hemophilia Treatment Drugs Market @ https://www.zionmarketresearch.com/sample/hemophilia-treatment-drugs-market
The global hemophilia treatment drugs market is segregated on the basis of product type, disease type, and distribution channel. The product type segment is divided into RCFC, PDCFC, desmopressin, and antifibrinolytic agent. The RCFC segment is anticipated to dominate the hemophilia treatment drugs market. The preference for recombinant factor concentrates has increased as it has a low risk of infections thus fuelling the growth of this segment. The PDCFC is also expected to show a significant growth. Plasma derivatives are fractions that are isolated from human blood which contains three main components namely immunoglobin, albumin, and clotting factors. In countries such as China and Japan, there is an increase in demand for this concentrates which is expected to fuel the growth of this segment.
The disease type segment includes hemophilia B, hemophilia A, and others. In 2016, there were approximately 149,800 patients suffering from hemophilia A.
Download Free PDF Research Report Brochure @ https://www.zionmarketresearch.com/requestbrochure/hemophilia-treatment-drugs-market
Due to the increase in the number of patients of hemophilia A, this segment is expected to lead the disease type segment. Based on distribution channel, the market is further segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment is anticipated to lead the global hemophilia treatment drugs market.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the regional segments of global hemophilia treatment drugs market. North America is anticipated to remain the leading region over the forecast period due to the rapid increase in awareness about hemophilia and the technologies used to treat hemophilia. The Asia Pacific is expected to show rapid growth due to the increase in the number of patients and improving healthcare infrastructure. Europe is expected to show a significant growth in the forecast period due to the technological advancements in research and development of treatment drugs. Latin America and the Middle East & Africa are also expected to show a steady increase due to the increase in hemophilia patients.
Some of the key players in the global hemophilia treatment drugs market are Shire Plc., Novo Nordisk A/S, Pfizer, Bayer AG, CSL Ltd., Biogen, and others. Major players are frequently engaged in the development of new drugs for the treatment of hemophilia.